J Rheumatol 2011;38;1223-1534
http://www.jrheum.org/content/38/7.citation

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Early Arthritis
and to Modified Citrullinated Vimentin in Early RA and Very Observations from the RADIUS Registry
A Large Retrospective Multicenter Study in China

Metropolitan City Rheumatoid Arthritis Disease Susceptibility and Dyslipidemia in RA?
Lymphotoxin- Challenges in Diagnosing Latent TB Infection in Patients
Who's Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis J.E. Homik

Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment? E. Lubrano, S. D’Angelo, A. Spadaro, C. Palazzi, I. Olivieri

Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus? C.S. Lau

Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression A. Mak, Y. Liu, R.C.-M Ho

Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos

Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms A.D. Askanase, I. Castrejón, T. Pincus

Late-age Onset SSc R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers

Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group


Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy. A Randomized Controlled Trial D.D. Gladman, P. Rahman, R.J. Cook, et al

Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation S.J. Pedersen, P. Chiochwanawisawakit, R.G.W. Lambert, M. Østergaard, W.P. Maksymowych


Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene S. Borghini, M. Fiore, M. Di Duca, et al

Free online via JRheum Full Release option
Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors D.S. Goldfarb, P.A. MacDonald, B. Hunt, L. Gunawardhana ............... 1385

Consistency of Knee Pain and Risk of Knee Replacement: The Multicenter OA Study

Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons
A.A. Khan, L.P. Rios, G.K.B. Sandor, et al .................. 1396

Longterm Therapeutic Response to Milnacipran Treatment for FM: A European 1-Year Extension Study Following a 3-Month Study J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group ........... 1403

Specialized Rheumatology Nurse Substitutes for Rheumatologists in the Diagnostic Process of FM: A Cost-Consequence Analysis and RCT

Pedicatric Rheumatology

Heterotopic Ossification of the TMJ in JIA
S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace ................ 1423

MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Ku, J-L. Huang ............... 1429

Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Rituximab Registry B. Bader-Meunier, H. Decaluwe, C. Barberias, et al. for the Club Rhumatismes et Inflammation ................. 1436

Development of IBD in Patients with JIA Treated with Etanercept T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al .............. 1441

Images in Rheumatology

Fluorescence Optical Imaging of Juvenile Arthritis
S.G. Werner, H-E. Langer, G. Horneff ................................ 1447

OMERACT 10

10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010
Introduction ..................................................... 1448

Disease-specific Outcomes


Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities N. Dalbeth, F.M. McQueen, J.A. Singh, et al. .................. 1458

Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?
L.K. Stamp, P.P. Khanna, N. Dalbeth, et al. ..................... 1462


The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
P.A. Merkel, S.Z. Aydin, M. Boers, et al ...................... 1480

Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update
P.J. Mease, D.J. Clauw, R. Christensen, et al. and the OMERACT Fibromyalgia Working Group .................. 1487

Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG

Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde ............. 1502


Developing Disease Activity and Response Criteria in CTD-related ILD L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group .................. 1514

Correspondence

Where in the World is Oral Triamcinolone? L. Roger .......... 1519
Reply R. Aitken .................................................... 1519

Lupus Related Longitudinal Myelitis
D.M. Wingerchuk, B.G. Weisman ................................ 1520
Reply P. Zotos ...................................................... 1521

Who Discovered the ESR? A. Grzybowski, J.J. Sak ................ 1521
Reply E.L. Matteson, C.S. Crowson ............................... 1523

Letters


Acute Presentation of Tophaceous Myelopathy
E. Levin, K. Hurth, R. Joshi, R. Brasington ................. 1525

AS Refractory to TNF Blockade Responds to Tocilizumab
J-D. Cohen, R. Ferreira, C. Jorgensen ......................... 1527

Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis
M. Uh, I.A. McCormick, J.T. Kelsall ......................... 1528

Primary Aldosteronism Simulating Polymyositis
Y-C. Tang, S-K. Wang, W-L. Yuan ................................ 1529

Corrections

Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial J.A. Singh, M.L. Mahowald, S. Noorbalaocchi .................. 1534


Meetings in Rheumatology